Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus

Hepatology Research

Volumn 49, Issue 5, 2019, Pages 531-539

  Akuta, Norio ^a   Kawamura, Yusuke ^a   Watanabe, Chizuru ^a   Nishimura, Akihiro ^a   Okubo, Minoru ^a   Mori, Yasumichi ^a   Fujiyama, Shunichiro ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Kobayashi, Mariko ^a   Saitoh, Satoshi ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

diabetes mellitus; exosome; microRNA 122; nonalcoholic steatohepatitis; prospective study; SGLT2I

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CANAGLIFLOZIN; CHOLESTEROL; GLUCOSE; MICRORNA; MICRORNA 122; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL OUTCOME; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; ECHOGRAPHY; EXOSOME; FEMALE; GLUCOSE METABOLISM; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER STIFFNESS; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEATOSIS; TRANSIENT ELASTOGRAPHY; WAIST CIRCUMFERENCE;

EID: 85061335533     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.13304     Document Type: Article

References (36)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–1231.
2. Williams R. Global changes in liver disease. Hepatology 2006; 44: 521–526.
3. Kawamura Y, Arase Y, Ikeda K et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253–261.
4. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475–485.
5. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3–13.
6. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675–1685.
7. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956–965.
8. Loomba R, Lawitz E, Mantry PS et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 2018; 67: 549–559.
9. Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 6355–6360.
10. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669–672.
11. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539–545.
12. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.
13. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232–1238.
14. Akuta N, Watanabe C, Kawamura Y et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun 2017; 1: 46–52.
15. Akuta N, Kawamura Y, Suzuki F et al. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 2016; 10: 647–656.
16. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937.
17. Pirola CJ, Fernández Gianotti T, Castaño GO et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800–812.
18. Willeit P, Skroblin P, Moschen AR et al. Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 2017; 66: 347–357.
19. Rayner KJ, Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res 2013; 54: 1174–1181.
20. Morishita A, Masaki T. MicroRNAs as possible biomarkers for hepatocellular carcinoma. Hepatol Res 2018; 48: 499–501.
21. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.
23. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60: 565–575.
24. Boursier J, Zarski JP, de Ledinghen V et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182–1191.
25. Kumagai E, Korenaga K, Korenaga M et al. Appropriate use of virtual touch quantification and FibroScan M and XL probes according to the skin capsular distance. J Gastroenterol 2016; 51: 496–505.
26. Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J Clin Endocrinol Metab 2000; 85: 4396–4402.
27. Yanagisawa K, Omori Y, Fukushima S, Iwasaki N, Hashimoto N, Iwamoto Y. The over 50 year clinical course of a patient with slowly progressive type 1 diabetes (SPIDDM). Endocr J 2010; 57: 181–183.
28. Paglialunga S, Guerrero A, Roessig JM, Rubin P, Dehn CA. Adding to the spectrum of insulin sensitive populations for mixed meal tolerance test glucose reliability assessment. J Diabetes Metab Disord 2016; 15: 57.
29. TaqMan Small RNA Assays Protocol. Foster City, CA: Applied Biosystems. 2011.
30. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298–301.
31. Yu S, Liu Y, Wang J et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: 2084–2092.
32. Seko Y, Sumida Y, Sasaki K et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol 2018; 53: 140–151.
33. Miquelestorena-Standley E, Tallet A, Collin C et al. Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection. Hepatol Res 2018; 48: 566–573.
34. Joannides CN, Mangiafico SP, Waters MF, Lamont BJ, Andrikopoulos S. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metab 2017; 19: 1135–1146.
35. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014; 57: 891–901.
36. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.